NCT02172352View on ClinicalTrials.gov

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

May 31, 1999

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Ba 679 BR low dose

DRUG

Ba 679 BR middle dose

DRUG

Ba 679 BR high dose

DRUG

Placebo inhalation powder

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY